| Literature DB >> 34543704 |
D G Partridge1, A Sori2, D J Green2, R Simpson2, B Poller3, M Raza4, H Kaur5, H Jessop5, B Colton5, A Nield5, C M Evans6, A Lee2.
Abstract
Prevention of respiratory viral infection in stem cell transplant patients is important due to its high risk of adverse outcome. This single-centre, mixed methods study, conducted before the severe acute respiratory syndrome coronavirus-2 pandemic, explored the barriers and facilitators to a policy of universal mask use by visitors and healthcare workers, and examined the impact of the first year of introduction of the policy on respiratory viral infection rates compared with preceding years, adjusted for overall incidence. Education around universal mask use was highlighted as being particularly important in policy implementation. A significant decrease in respiratory viral infection was observed following introduction.Entities:
Keywords: Barriers; COVID-19; Coronavirus; Facemask; Infection prevention and control; Influenza; Mask; Neutropenia; Parainfluenza; Qualitative; RSV; Respiratory virus; Rhinovirus; Stem cell transplant
Mesh:
Year: 2021 PMID: 34543704 PMCID: PMC8447542 DOI: 10.1016/j.jhin.2021.09.005
Source DB: PubMed Journal: J Hosp Infect ISSN: 0195-6701 Impact factor: 3.926
Demographics of patients undergoing stem cell transplantation in pre- and post-intervention periods
| Pre-intervention | Post-intervention | ||
|---|---|---|---|
| Number of transplants | 412 | 138 | |
| Sex (% female) | 154 (37.4%) | 58 (42.0%) | 0.38 |
| Mean age (years) | 55.35 | 55.64 | 0.84b |
| Number (%) allogeneic | 122 (29.6%) | 37 (26.8%) | 0.60 |
| Underlying disease | |||
| Multiple myeloma | 200 (48.5%) | 72 (52.2%) | 0.52 |
| Lymphoma | 62 (15.0%) | 21 (15.2%) | >0.99 |
| Acute myeloid leukaemia | 53 (12.9%) | 15 (10.9%) | 0.64 |
| Acute lymphoblastic leukaemia | 18 (4.4%) | 4 (2.9%) | 0.61 |
| Myelodysplastic syndrome | 14 (3.4%) | 2 (1.4%) | 0.38 |
| Myelofibrosis | 7 (1.7%) | 1 (0.7%) | 0.68 |
| Chronic myeloid leukaemia | 6 (1.5%) | 1 (0.7%) | 0.82 |
| Aplastic anaemia | 3 (0.7%) | 3 (2.2%) | 0.35 |
| Other including non-haematological (e.g. multiple sclerosis) | 49 (11.9%) | 19 (13.8%) | 0.68 |
aP-values are a two-proportion Z-test with Yates' continuity correction, with the exception of b which is a two-sample t-test.
Numbers and rates of respiratory viral infection in the pre- and post-intervention periods with and without adjustment for overall population incidence
| Virus | Number of diagnoses in SCT recipients | Rate per 100 SCT recipients | Total laboratory diagnoses | Population-adjusted pre-intervention rate per 100 patients | Risk difference per 100 patients (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-intervention ( | Post-intervention ( | Pre-intervention | Post-intervention | Pre- intervention (2015–18) | Post- intervention (2019–20) | ||||
| Influenza A | 3 | 0 | 0.73 | 0.00 | 1710 | 1303 | 1.66 | 0.279 | 1.66 (-0.05 to 3.38) |
| Influenza B | 2 | 0 | 0.49 | 0.00 | 1210 | 46 | 0.06 | >0.99 | 0.06 (-0.23 to 0.34) |
| Parainfluenza 1 | 2 | 0 | 0.49 | 0.00 | 145 | 97 | 0.97 | 0.558 | 0.97 (-0.46 to 2.41) |
| Parainfluenza 2 | 3 | 1 | 0.73 | 0.72 | 220 | 89 | 0.88 | >0.99 | 0.16 (-1.68 to 2.00) |
| Parainfluenza 3 | 10 | 2 | 2.43 | 1.45 | 616 | 299 | 3.53 | 0.341 | 2.09 (-1.07 to 5.24) |
| Parainfluenza 4 | 2 | 1 | 0.49 | 0.72 | 129 | 58 | 0.65 | >0.99 | -0.07 (-1.75 to 1.62) |
| Total parainfluenza | 17 | 4 | 4.13 | 2.90 | 1110 | 543 | 6.06 | 0.224 | 3.16 (-0.95 to 7.27) |
| Human metapneumovirus | 2 | 1 | 0.49 | 0.72 | 648 | 414 | 0.93 | >0.99 | 0.21 (-1.69 to 2.10) |
| Coronavirus | 11 | 2 | 2.67 | 1.45 | 1469 | 484 | 2.64 | 0.635 | 1.19 (-1.82 to 4.20) |
| Respiratory syncytial virus | 5 | 5 | 1.21 | 3.62 | 597 | 594 | 3.62 | >0.99 | 0.00 (-3.60 to 3.60) |
| Rhinovirus | 24 | 4 | 5.83 | 2.90 | 2332 | 1162 | 8.71 | 0.037 | 5.81 (1.42–10.20) |
| Total respiratory viral infections | 64 | 16 | 15.53 | 11.59 | 9076 | 4546 | 23.34 | 0.005 | 11.75 (4.54–18.96) |
| Inpatient respiratory viral infections | 54 | 10 | 13.11 | 7.25 | 9076 | 4546 | 19.69 | 0.001 | 12.45 (6.18–18.72) |
SCT, stem cell transplant.
P-values are a two-proportion Z-test with Yates' continuity correction between the observed post-intervention rate per 100 SCT recipients (fourth column of data) and the adjusted pre-intervention rate per 100 SCT recipients (seventh column of data).